FOCL FocalTherics - ADR

$FOCL I listened the conference call. Over all the call was what I expected. nothing more or less. You could have come to the same conclusion by watching how Focl was trading before before earnings. the positives are still there. the growth continues (with some hiccups along the way) the expenses continue to be somewhat high. However the initial growth phase requires this type of expenditures. Their focus to continue the expansion of the use of the platform to other indications is the right approach. however the costs are being incurred now for future revenues. Patience continues to be the theme here. as long as they grow, the costs will fall in line. do not forget they are in the razor blade business. with every machine they sell there is a perpetual income from the consumables and service. I am a buyer at this price

$FOCL STICK A FORK IN THEM!!!! THIS PIECE OF GARBAGE IS DONE! EMPLOYEES KEEP LINING THEIR POCKETS!! FOCL/EDAP SUCKS

$FOCL honestly this was a very mid Q3 (nothing bad, nothing good). The revenue miss was because of the delayed 3 sales. But they stated the sales were completed in Q4, if the sales were on time the revenue would have been in-line with estimates (so I’m not taking it as a true revenue miss as it was out of the company’s hands) Glad to see operational demand is still above 30% and has maintained that for some time now as that’s the true revenue grower for long term. I’m not too worried about the top revenue revision as the bottom remains the same (if it was a total range change then I’d have a huge problem with that, as they previously stated that they expected revenues to be halfway between $50-$54 million which is where they have set the boundary line so it’s really not changing any previously believed metric) The only thing I really care about is end of year: HIFUSA results Endometriosis results Initial BPH study results These are the biggest drivers for long term

$FOCL Background on sales:(This was reported by management during EDAP's Q2 2026 earnings call on August 13, 2026. ) As of June 30, 2026, EDAP (NASDAQ: EDAP) had 184 Focal One HIFU systems installed worldwide. Breakdown: 96 systems in the United States. 88 systems internationally. 184 systems total worldwide. For context, the installed base grew from: 107 units at year-end 2023. 130 units at year-end 2024. 165 units at year-end 2025. I hope they install 47 units in 2026, to make 212 units installed by 12/31/2025. If FOCL meets this number, I expect them to be profitable fairly soon.... Please do your own DD Bottom line: EDAP has approximately 184 installed HIFU systems worldwide, demonstrating substantial commercial expansion.

$FOCL Wow, no posts for almost 3 weeks.... guess I will postulate: How much of the DIE market can HIFU service ? rough estimates: (please do your own dd, and not rely on these..this is food for thought ) Women with endometriosis worldwide. ~190M Estimated share with deep disease ~20% or 38M IMARC estimates the overall global endometriosis market at US$2.6 billion in 2025, Att a guess 20% of 2.6B ~$500M market potential for DIE HIFU vs current opportunities? (Source from AI) * Diagnostic market: specialist ultrasound, MRI and diagnostic services. * Treatment market: hormonal therapies, pain management and follow-up care. * Surgical market: laparoscopic excision, surgical instruments and specialist multidisciplinary care for complex disease.

$FOCL Design double-blind, randomized, study comparing HIFU to a sham procedure in 60 patients. Setting We tested the ability of HIFU to shrink the lesions, relieve pain, and alleviate digestive symptoms. Patients or Participants 32 French patients underwent HIFU treatment and 28 a sham treatment then evaluations, at months one and three, of intensity of acute pelvic pain and other symptoms. In an open-label extension phase, 24 sham-treated patients underwent HIFU treatment then same evaluations. All participants had MRI at M3 and a follow-up at Year 1 and/or Year 2 per available follow-up. Interventions under general anesthesia, the HIFU probe was introduced trans-ectally. After scanning of the lesion, patients were randomized to reeive either HIFU treatment or sham procedure, in a double blind design involving both the physician and the patient.

$FOCL Total revenue for the third quarter of 2026 was $9.8 million, compared to $7.8 million for the same period in 2025, representing an increase of 26% year-over-year. Operating loss was $7.8 million for the third quarter of 2026, compared to $6.7 million in the prior year period. Net loss was $4.5 million for the third quarter of 2026, or ($0.10) per share, compared to a net loss of $5.9 million, or ($0.16) per share in the prior year period.

$FOCL this company needs out of France entirely. Whole country is being destroyed in protests right now.

$FOCL HIFU Treatment of Rectal Endometriosis: Short- and Long-Term Results of a Double-Blind Randomised Trial Versus Sham Procedures

$FOCL its many, many years of slight improvements in revenue, a percentage or two above inflation. All of this under direct competition with TULSA and others. In the meantime, they continue to hemmorage cash. Another offering in a year? It helps patients, but from investor perspective a futile enterprise.

$FOCL Q3 '26 Earnings Results & Recap FocalTherics narrowed full-year 2026 revenue guidance to $50M, representing 34% to 39% growth over 2025, from the prior range of $50M.

$FOCL this can't be good...earnings announced after the close??? That's the first time in a long time.....I wonder why they are doing it this way instead of before the market open?? GO FOCL!

$FOCL looking at today's 13f/g filings, at least we know that about 4 million of the 8+ million they issued in the last dilution are in good hands.